To include your compound in the COVID-19 Resource Center, submit it here.

Arca biopharma, Nuvelo deal

Nuvelo and cardiovascular company Arca agreed to reverse merge. Arca shareholders will own 67% of the combined company, and Nuvelo shareholders will

Read the full 227 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE